Article Text

Download PDFPDF

Correction: First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hermann V, Batalov A, Smakotina S, et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Science & Medicine 2019;6:e000354. doi: 10.1136/lupus-2019-000354.

The authors want to alert the readers to the error identified in Supplementary file 7.

The original Supplementary file 7 included the number of patients (n) in the full analysis set for each cenerimod dosage. The revised file has been amended to show the correct n numbers, which is the number of patients included in the modified pharmacodynamics set (mPD set).